Thrombotic Thrombocytopenic Purpura News and Research

RSS
MGH investigators use new drug to save the life of patient with immune thrombotic thrombocytopenic purpura

MGH investigators use new drug to save the life of patient with immune thrombotic thrombocytopenic purpura

Promising nanobodies against COVID-19 produced by llamas

Promising nanobodies against COVID-19 produced by llamas

Scientists isolate anti-COVID-19 nanobodies produced by a llama

Scientists isolate anti-COVID-19 nanobodies produced by a llama

Study: Caplacizumab not cost effective for treating thrombotic thrombocytopenic purpura

Study: Caplacizumab not cost effective for treating thrombotic thrombocytopenic purpura

Nanobodies: unharnessed potential in COVID-19 treatment

Nanobodies: unharnessed potential in COVID-19 treatment

Critically ill COVID-19 patients experience novel platelet-activating immune complexes, study finds

Critically ill COVID-19 patients experience novel platelet-activating immune complexes, study finds

Acute kidney injury on the rise in hospitalized pregnant women

Acute kidney injury on the rise in hospitalized pregnant women

Researchers find synergistic connection between two deadly blood-clotting diseases

Researchers find synergistic connection between two deadly blood-clotting diseases

First therapy indicated for treating adults with rare blood clotting disorder receives FDA approval

First therapy indicated for treating adults with rare blood clotting disorder receives FDA approval

Researchers highlight potential therapy for treating rare, deadly blood-clotting disorder

Researchers highlight potential therapy for treating rare, deadly blood-clotting disorder

FDA approves first adjuvant treatment to reduce risk of kidney cancer recurrence

FDA approves first adjuvant treatment to reduce risk of kidney cancer recurrence

European Commission approves extended indication for Amgen's Kyprolis (carfilzomib) for the treatment of relapsed multiple myeloma patients

European Commission approves extended indication for Amgen's Kyprolis (carfilzomib) for the treatment of relapsed multiple myeloma patients

UAB researcher awarded NIH grant to study pathogenesis of thrombotic microangiopathy

UAB researcher awarded NIH grant to study pathogenesis of thrombotic microangiopathy

Omeros reports additional positive data from OMS721 Phase 2 trial for treatment of thrombotic microangiopathies

Omeros reports additional positive data from OMS721 Phase 2 trial for treatment of thrombotic microangiopathies

Omeros' OMS721 granted FDA Fast Track designation for treatment of atypical hemolytic uremic syndrome

Omeros' OMS721 granted FDA Fast Track designation for treatment of atypical hemolytic uremic syndrome

Study points to potential treatment for thrombotic thrombocytopenic purpura

Study points to potential treatment for thrombotic thrombocytopenic purpura

New ASH report outlines several models for 'systems-based clinical hematologist'

New ASH report outlines several models for 'systems-based clinical hematologist'

Platelet transfusion treatment increases death in people with certain rare blood cell disorders

Platelet transfusion treatment increases death in people with certain rare blood cell disorders

FDA clears Omeros' OMS721 IND for inhibition of complement‑mediated TMAs

FDA clears Omeros' OMS721 IND for inhibition of complement‑mediated TMAs

Omeros submits investigational new drug to initiate OMS721 Phase 2 clinical program

Omeros submits investigational new drug to initiate OMS721 Phase 2 clinical program

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.